Form 8-K - Current report:
SEC Accession No. 0001599298-25-000064
Filing Date
2025-04-23
Accepted
2025-04-23 08:54:14
Documents
19
Period of Report
2025-04-23
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K smmt-20250423.htm   iXBRL 8-K 29509
2 EX-99.1 a2025_prx0423xivonescima.htm EX-99.1 14916
7 a2025_prx0423xivonescima001.jpg GRAPHIC 272898
8 a2025_prx0423xivonescima002.jpg GRAPHIC 248856
9 a2025_prx0423xivonescima003.jpg GRAPHIC 211105
10 a2025_prx0423xivonescima004.jpg GRAPHIC 221552
  Complete submission text file 0001599298-25-000064.txt   1519328

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20250423.xsd EX-101.SCH 2042
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT smmt-20250423_def.xml EX-101.DEF 14787
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20250423_lab.xml EX-101.LAB 26043
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20250423_pre.xml EX-101.PRE 15429
21 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20250423_htm.xml XML 2735
Mailing Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131
Business Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131 305-203-2034
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

EIN.: 371979717 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 25859339
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)